Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001213 · ClinicalTrials.gov registry record · Phase 2
Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis
A Phase 2 study, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
NCT00001213 is a Phase 2 study that has completed, run by National Eye Institute (NEI). The registered enrollment target is 328 participants.
The verdict
NCT00001213, a Phase 2 study, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
Study Summary
Cystinosis is an inherited disease that results in poor growth and kidney disease, among other things. The damage to the kidneys and other organs is thought to be due to accumulation of cystine inside the cells of various body tissues. This chemical also accumulates in the cornea-the covering of the eye over the pupil and iris. After 10 to 20 years, the corneas of some patients become so packed with crystals that the surfaces may become irregular, occasionally causing small, painful breaks. Patients enrolled in a NIH study on cystinosis are receiving the drug cysteamine. Taken by mouth, this drug reduces cystine in some tissues, but not in the cornea. This study began in 1986 to test whether cysteamine eye drops could prevent or reduce corneal cystine crystals in these patients. The drops have been very effective in removing crystals and reducing pain in patients who take the medication as directed. Patients who do not take the medication as prescribed do not benefit. After the effectiveness of the drops was proven, the main purpose was modified to continue to evaluate the long-term safety and effectiveness of cysteamine eye drops for treating cystine crystals in the corneas of patients with cystinosis until the drops are approved by the Food and Drug Administration (FDA). When the New Drug Application (NDA) for the Sigma-Tau standard formulation is granted, this protocol will be terminated.
Interventions
- DRUG Cysteamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 1986-04 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001213
The ClinicalTrials.gov registry entry for NCT00001213 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cysteamine is the first listed.
NCT00001213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001213 about?
NCT00001213 is a clinical study titled "Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis". Cystinosis is an inherited disease that results in poor growth and kidney disease, among other things. The damage to the kidneys and other organs is thought to be due to accumulation of cystine inside the cells of various body tissues. This chemical also accumulates in the cornea-the covering of the...
What is the current status of trial NCT00001213?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 1986-04. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00001213?
The interventions under investigation include: Cysteamine (DRUG).
Who is sponsoring clinical trial NCT00001213?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.